CrystalGenomics' pioneer Fabl inhibitor passes first MRSA efficacy hurdle
This article was originally published in Scrip
Executive Summary
CrystalGenomics' first-in-class pipeline antibiotic CG400549 has shown promising signs of efficacy in its first clinical trial designed to measure this, putting the oral Fabl inhibitor a step closer to one day challenging big sellers such as Pfizer's Zyvox (linezolid).